Ozempic semaglutide patent expiration date?

Short answer

The above dates are the expiry dates for the U.S. patents that cover the active ingredient, formulation, and delivery system for Ozempic. The “Ozempic” brand name itself is protected by trademark, which can last indefinitely as long as it is in use.

Why the dates matter

• Active‑ingredient patents (e.g., US 8,234,170) prevent other companies from making or selling semaglutide in the U.S. until the term ends.
• Formulation & device patents protect the specific 0.25 mg/0.5 mg/1 mg pre‑filled pen format and the way it is administered.
• After the last of these patents expires, generics can begin to seek approval (subject to FDA review and any exclusivity periods that may still apply).

Practical timeline

Bottom line: The core active‑ingredient patents for semaglutide will expire in June 2026. Patents covering the Ozempic formulation and delivery device run until 2030–2034. Generics are unlikely to launch before those later expirations, even though the active‑ingredient patent lapses earlier.

How to verify

1. USPTO Patent Database – search the patent numbers above to confirm filing, publication, and expiration dates.
2. FDA’s Orange Book – lists drug exclusivities; for Ozempic, you’ll see the 6‑year exclusivity that started with its approval in 2017 (expires 2023), but that does not affect the underlying patents.
3. European Patent Register (EPO) – for EU‑specific expirations; the dates usually align with the U.S. terms but may vary slightly.

If you need the exact expiration dates in a different jurisdiction (e.g., Canada, EU, Japan), let me know and I can pull the corresponding data for you.